GlassScriptPhysician profile
Dawn D Smiley-Byrd
NPI 1134238827
$385,184.09
in general payments reported to CMS, 2019-2025
44 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $50K · 2021: $68K · 2022: $75K · 2023: $21K · 2024: $29K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Travel and Lodging: $10K · Food and Beverage: $4,535 · Consulting Fee: $2,205 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,488.41 |
| Travel and Lodging | $10,253.48 |
| Food and Beverage | $4,534.81 |
| Consulting Fee | $2,205.00 |
| Education | $210.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $274,169.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $42,741.97 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35,135.15 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $21,393.12 | 2019-2025 | |
| Corcept Therapeutics | $2,787.38 | 2019-2024 | Korlym |
| Eli Lilly and Company | $2,000.00 | 2021 | |
| Medtronic, INC. | $1,638.79 | 2021-2023 | Minimed 780g |
| Lifescan, INC. | $1,137.00 | 2021 | |
| Insulet Corporation | $604.77 | 2019-2023 | Omnipod |
| Lilly USA, LLC | $591.69 | 2019-2023 | Lyumjev |
| Amgen INC. | $538.57 | 2019-2023 | Prolia, Evenity, Repatha |
| Mannkind Corporation | $423.49 | 2019-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.44 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $234.37 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $167.63 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $129.52 | 2019-2020 | |
| Abbott Laboratories | $97.62 | 2019-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $86.70 | 2019-2023 | Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $80.30 | 2019-2023 | Unithroid |
| Dexcom, INC. | $79.50 | 2019-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $61.36 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $60.77 | 2022-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.31 | 2020-2022 | |
| Optos, INC. | $59.31 | 2020-2021 | |
| Antares Pharma, INC. | $56.55 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Horizon Therapeutics Plc | $55.03 | 2023 | Tepezza |
| Janssen Pharmaceuticals, INC | $48.01 | 2019 | |
| Acerus Pharmaceuticals Corporation | $47.88 | 2020-2021 | |
| Shire North American Group INC | $45.76 | 2019 | |
| Vivus LLC | $42.79 | 2021-2022 | |
| Abbvie INC. | $39.25 | 2019-2022 | |
| Radius Health, INC. | $38.92 | 2019-2020 | |
| Amryt Pharma Holdings LTD | $37.42 | 2022-2023 | Mycapssa |
| Endo Pharmaceuticals INC. | $35.94 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $32.91 | 2020-2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Alexion Pharmaceuticals, INC. | $32.52 | 2022-2023 | Strensiq |
| Ascensia Diabetes Care US INC. | $21.57 | 2024 | |
| Amarin Pharma, INC. | $20.65 | 2021 | |
| Zealand Pharma US, INC. | $20.00 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $19.21 | 2019 | |
| Valeritas, INC. | $18.83 | 2019 | |
| Acella Pharmaceuticals, LLC | $16.55 | 2022 | |
| Companion Medical, INC. | $16.49 | 2019 | |
| Cequr Corporation | $8.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Smiley-Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.